Literature DB >> 16154434

The factor V Leiden mutation, high factor VIII, and high plasminogen activator inhibitor activity: etiologies for sporadic miscarriage.

Charles J Glueck1, Joel Pranikoff, Dawit Aregawi, Mofiz Haque, Binghua Zhu, Trent Tracy, Ping Wang.   

Abstract

We hypothesized that the thrombophilic G1691A factor V Leiden gene mutation was a common significant cause of sporadic first trimester miscarriage. We compared thrombophilia and hypofibrinolysis in 92 women (85 white, 5 black, 2 other) with 1 or more pregnancies and 1 miscarriage (143 live births, 92 miscarriages) (cases) and in 380 female controls (355 white, 21 black, 4 other) with 1 or more pregnancies and 0 miscarriages (964 live births). We used polymerase chain reaction techniques to characterize thrombophilic gene mutations (G1691A V Leiden [FV], G20210A prothrombin, C677T/A1298C MTHFR) and hypofibrinolytic gene mutations (plasminogen activator inhibitor [PAI-1] activity 4G4G). We carried out serologic measures of thrombophilia (homocysteine, anticardiolipin antibodies [ACLA] immunoglobulin G and immunoglobulin M, lupus anticoagulant, factor VIII, factor XI, protein C, total and free protein S, antithrombin III) and hypofibrinolysis (plasminogen activator inhibitor activity [PAI-Fx], lipoprotein[a]). Of the 380 controls, 6 (1.6%) had FV heterozygosity vs 12 heterozygous and 2 homozygous FV cases (15.2% [14/92]; P < .0001). Plasminogen activator inhibitor activity was high (> or =21.1 U/mL) in 21 (33%) of 63 cases vs 27 (18%) of 152 controls (P = .013). Factor VIII was high (>150%) in 15 (31%) of 48 cases vs 19 (18%) of 103 controls (P = .079). By logistic regression, with age and factor VIII (categorical [< or =150%, >150%]) as explanatory variables and group (cases, controls) as the dependent variable, after adjusting for age, high factor VIII was a significant predictor for miscarriage (odds ratio, 3.28; 95% confidence interval, 1.34-8.04; P = .01). There were no other group differences (P > .05) in measures of thrombophilia and hypofibrinolysis. After unexplained sporadic first trimester miscarriage, we suggest that measurements be done of the FV mutation, PAI-Fx, and factor VIII, etiologies for sporadic miscarriage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16154434     DOI: 10.1016/j.metabol.2005.04.024

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  A likelihood model that accounts for censoring due to fetal loss can accurately test the effects of maternal and fetal genotype on the probability of miscarriage.

Authors:  Colin I O'Donnell; Charles J Glueck; Tasha E Fingerlin; Deborah H Glueck
Journal:  Hum Hered       Date:  2008-10-17       Impact factor: 0.444

2.  Long term anticoagulation (4-16 years) stops progression of idiopathic hip osteonecrosis associated with familial thrombophilia.

Authors:  Charles J Glueck; Richard A Freiberg; Robert Wissman; Ping Wang
Journal:  Adv Orthop       Date:  2015-01-29

3.  Diagnostic ramifications of ocular vascular occlusion as a first thrombotic event associated with factor V Leiden and prothrombin gene heterozygosity.

Authors:  Samantha Schockman; Charles J Glueck; Robert K Hutchins; Jaykumar Patel; Parth Shah; Ping Wang
Journal:  Clin Ophthalmol       Date:  2015-04-03

4.  Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes.

Authors:  Will S Kurtz; Charles J Glueck; Robert K Hutchins; Robert A Sisk; Ping Wang
Journal:  Clin Ophthalmol       Date:  2016-05-23

5.  Thrombophilia and retinal vascular occlusion.

Authors:  Charles J Glueck; Robert K Hutchins; Joel Jurantee; Zia Khan; Ping Wang
Journal:  Clin Ophthalmol       Date:  2012-08-28

6.  Retinal vascular occlusion: a window to diagnosis of familial and acquired thrombophilia and hypofibrinolysis, with important ramifications for pregnancy outcomes.

Authors:  Stephan G Dixon; Carl T Bruce; Charles J Glueck; Robert A Sisk; Robert K Hutchins; Vybhav Jetty; Ping Wang
Journal:  Clin Ophthalmol       Date:  2016-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.